EP Patent

EP0712863B1 — Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use

Assigned to Centro de Immunologia Molecular · Expires 2002-02-27 · 24y expired

What this patent protects

New humanized and chimeric monoclonal antibodies that recognize EGF-R and comprise an artificial sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin. The hypervariable regions of both monoclonal antibodies is the following amino acid sequence…

USPTO Abstract

New humanized and chimeric monoclonal antibodies that recognize EGF-R and comprise an artificial sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin. The hypervariable regions of both monoclonal antibodies is the following amino acid sequence: <IMAGE> Use of the antibodies for therapeutical and diagnostic purposes.

Drugs covered by this patent

Patent Metadata

Patent number
EP0712863B1
Jurisdiction
EP
Classification
Expires
2002-02-27
Drug substance claim
No
Drug product claim
No
Assignee
Centro de Immunologia Molecular
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.